NSCLC as the Primary Arena for ADC Development

This document is a technical report that analyzes the current landscape of antibody-drug conjugates (ADCs) in non-small cell lung cancer (NSCLC). It outlines the dynamics influencing ADC strategies in NSCLC, identifying it as a high-activity area due to its combination of high incidence, biomarker segmentation, and late-line entry points. The report details three key dynamics: indication concentration, a Phase 3 conversion race, and payload convergence towards Topoisomerase-I (Topo-I) payloads. It presents data showing that NSCLC accounts for approximately 11.7% of ADC clinical activity, significantly more than other indications. The report notes that while three ADCs have received accelerated approval, the field remains early in regulatory maturity. It highlights the strategic implications of these trends, including the urgency created by recent approvals and the operational maturity of ADC development. The report concludes by discussing the competitive landscape and the importance of differentiation in a crowded market.